## Capsule Endoscopy

| Section                                           | Code    |
|---------------------------------------------------|---------|
| General Guidelines (CAPEND-0)                     |         |
| Crohn's Disease (CAPEND-1)                        |         |
| Celiac Disease (CAPEND-2)                         |         |
| Gastrointestinal Bleeding (CAPEND-3)              |         |
| Small Bowel Tumors (CAPEND-4)                     |         |
| Genetic Syndromes (CAPEND-5)                      |         |
| Patency Capsule (CAPEND-6)                        |         |
| Colon Capsule Endoscopy (CAPEND-7)                |         |
| Esophageal Capsule Endoscopy (CAPEND-8)           |         |
| Wireless Motility Capsule Endoscopy (CAPEND-9)    |         |

References
General Guidelines (CAPEND-0)

- eviCore’s Gastrointestinal Endoscopy Program applies an evidence-based approach to evaluate the most appropriate care for each individual. This evaluation requires submission of medical records pertinent to the treatment and/or services being requested by the provider.

- If the medical records provided do not provide sufficiently detailed information to understand the individual’s current clinical status, then the medical necessity for the request cannot be established and the request cannot be approved.

- Specific elements of an individual’s medical records commonly required to establish medical necessity should include, but are not limited to:
  - recent virtual or in-person clinical evaluation which includes a detailed history and physical examination pertinent to the current request
  - laboratory studies
  - imaging studies
  - pathology reports
  - procedure reports
  - reports from other providers participating in treatment of the relevant condition

- Adequate clinical information must be submitted to eviCore in order to establish medical necessity for gastrointestinal endoscopy services. Pertinent clinical evaluation (within 60 days) including a recent detailed history, physical examination, and/or laboratory and prior imaging studies should be performed prior to considering endoscopy. Other meaningful contact (telehealth visit, telephone or video call, electronic mail or messaging) by an established individual can substitute for an in-person clinical evaluation.

- eviCore reserves the right to change and update the Gastrointestinal Endoscopy Policy. The Policy undergo a formal review at least annually. eviCore’s policy is based upon major national and international association and society guidelines and criteria, peer reviewed literature, major treatises, as well as input from health plans, practicing academic and community-based physicians.

- This policy is not intended to supersede or replace sound medical judgment, but instead, should facilitate the identification of the most appropriate treatment given the individual’s clinical condition. This policy is written to cover most gastrointestinal endoscopic indications. However, the policy may not be applicable in certain clinical circumstances. Physician judgment may override the policy. Clinical decisions, including treatment decisions, are the responsibility of the individual and his/her provider. Clinicians are expected to use independent medical judgment, which takes into account the clinical circumstances to determine individual management decisions.

- All time intervals in this guideline refer to capsule endoscopy, unless otherwise stated.

- Requests for Open Access Endoscopy must meet criteria according to these guidelines.
Capsule endoscopy is not a term applicable to every study that utilizes an ingested capsule device. There are specific types of capsules, some of which have their own independent CPT® code (e.g. wireless motility capsule [CPT® 91112], colon capsule [CPT® 91113], etc.). The specific CPT® should be used for the corresponding capsule request.

New and Emerging Technologies
- Requests related to new and emerging technologies will be considered to determine whether they meet eviCore’s evidence-based guidelines.
  - If a specific CPT code does not exist for a new technology, the CPT code used in the request will be considered based on its typical procedure application.
  - Procedures which are inconsistent with established clinical standards or are requested for data collection and not used in direct clinical management are not supported.

State and federal legislations may need to be considered in the review of gastrointestinal endoscopy requests.

CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature, and other data are copyright 2019 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values, or related listings are included in the CPT® book. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.
Crohn’s Disease (CAPEND-1)

Capsule endoscopy (CPT® 91110) is indicated for the evaluation of known or suspected Crohn’s Disease in the following clinical scenarios:

- Clinical features consistent with Crohn’s Disease (i.e. chronic diarrhea or chronic abdominal pain with elevated biomarkers [ESR, CRP, fecal calprotectin, or lactoferrin], weight loss, +GI bleeding, with associated fatigue), negative ileocolonoscopy, and imaging studies (CT abdomen, CT abdomen/pelvis, or MRI abdomen) OR
- To assess for the possibility of small bowel disease (i.e. Crohn’s) in the presence of an indeterminate colitis OR
- Known Crohn’s Disease and ANY of the following:
  - Clinical features unexplained by ileocolonoscopy or imaging studies (CT abdomen, CT abdomen/pelvis, or MRI abdomen).
  - When assessment of small bowel mucosal healing beyond the reach of ileocolonoscopy is needed.
  - Suspected small bowel recurrence after colectomy, with negative or inconclusive ileocolonoscopy, CT, or MRI.

See: Background and Supporting Information

Capsule endoscopy is not indicated in individuals with:

- Chronic abdominal pain or diarrhea (≥ 28 days) as their only symptoms, and no evidence of elevated biomarkers associated with Crohn’s Disease.

Background and Supporting Information

Crohn’s Disease

- In a study, in individuals with both abdominal pain and diarrhea with positive inflammatory markers, the diagnostic yield of CE was 90.1% vs. 0% in those with negative inflammatory markers.

The consensus group of the Canadian Association of Gastroenterology concluded “CE is not warranted in most individuals who present with chronic abdominal pain the absence of positive tests for inflammatory markers or abnormal findings on endoscopy or imaging”.

Background and Supporting Information
Celiac Disease (CAPEND-2)

- Capsule endoscopy (CPT® 91110) is indicated for the evaluation of suspected celiac disease in the following clinical scenarios:
  - Individuals with positive serology and negative biopsy
  - Individuals with chronic diarrhea or suspected malabsorption and a contraindication to biopsy or EGD
  - Individuals with positive celiac serology and a contraindication to biopsy or EGD

- Capsule endoscopy (CPT® 91110) is indicated for the evaluation of confirmed celiac disease in the following clinical scenario:
  - New or continued symptoms (e.g., bloating, diarrhea, abdominal pain, weight loss, distension, evidence of malabsorption, anemia) despite adherence to 6 months of a gluten-free diet

Background and Supporting Information

- Celiac Disease
  - Celiac is an autoimmune disease in which the villi of the small intestine are damaged from eating gluten (found in wheat, barley, and rye).
  - Complications of celiac disease include ulcerative jejunitis, lymphoma, and small intestinal adenocarcinoma.
  - Screening blood tests include:
    - Anti-tissue transglutaminase antibody [anti-tTG], anti-endomysial antibody (EMA), total IgA count to assess for IgA deficiency, CBC to detect anemia, ESR, C-reactive protein, complete metabolic panel, vitamin D, E, B12 levels.

Gastrointestinal Bleeding (CAPEND-3)

- Capsule endoscopy (CPT® 91110) is indicated for the evaluation of GI bleeding in the following clinical scenarios:
  - Documented overt GI bleeding (observed blood per rectum, melena, or black stool excluding hematemesis) and negative findings on EGD and colonoscopy, CE is the next appropriate diagnostic step OR
  - Prior negative CE who have repeated obscure bleeding, CE can be repeated OR
  - Suspected obscure bleeding or UNEXPLAINED iron deficiency anemia (negative EGD and colonoscopy)
Small Bowel Tumors (CAPEND-4)

- Capsule endoscopy (CPT® 91110) is indicated for the evaluation of small bowel tumors in the following clinical scenario:
  - For the evaluation of known or suspected small bowel tumors (including genetic polyposis syndromes)

Genetic Syndromes (CAPEND-5)

- Capsule endoscopy (CPT® 91110) is indicated for the evaluation of Juvenile Polyposis Syndrome (defined as individuals with 5 or more juvenile polyps in the colorectum or any juvenile polyps in other parts of the GI tract, or evidence of SMAD4 or BMPR11A mutations) in the following clinical scenario:
  - Video capsule endoscopy can be performed periodically. Time interval not established.

- Capsule endoscopy (CPT® 91110) is indicated for the evaluation of Peutz-Jehgers Syndrome (defined as individuals with perioral or buccal pigmentation and/or 2 or more histologically characteristic hamartomatous polyps, or family history of PJS, or STK11 mutations) in the following clinical scenario:
  - Video capsule endoscopy at age 8. If no polyps, repeat at age 18, then every 2 years, or earlier if any symptoms occur\(^33\).

- Capsule endoscopy (CPT® 91110) is indicated for the evaluation of BMMRD (Biallelic Mismatch Repair Deficiency) in the following clinical scenario:
  - Video capsule endoscopy annually, beginning at age 8.

- Capsule endoscopy (CPT® 91110) is indicated for the evaluation of Familial Adenomatous Polyposis (FAP), Attenuated Familial Adenomatous Polyposis (AFAP) Syndromes, and MUTYH-Associated Polyposis in the following clinical scenarios:
  - For individuals found to have Spigelman Stages III and IV (see: EGD-1.16: Genetic Syndromes for table of Spigelman Stages), or before duodenectomy if this is being contemplated.
    - Repeat every 2 years
**Patency Capsule (CAPEND-6)**

- Patency Capsule
  - At this time, the use of a patency capsule for the pre-evaluation of the small intestine for capsule endoscopy is considered investigational/experimental

**Background and Supporting Information**

- Patency Capsule
  - While the American Gastroenterologic Association provides a recommendation for a patency capsule in individuals with known or suspected strictures of the small bowel, this is a conditional recommendation with very low quality of evidence for efficacy and low quality evidence for safety. The AGA notes:
  - “Therefore, the consensus group suggested that in individuals with obstructive symptomatology, imaging should be performed before CE. In individuals with negative imaging, most investigators will not use a patency capsule. In individuals with abnormalities, suggesting a high risk of capsule retention, patency capsules can be considered although some recent data have questioned their benefit.”
  - In addition, it has been reported that the positive predictive value of a patency capsule was relatively low at 44%.

**Colon Capsule Endoscopy (CAPEND-7)**

- Colon Capsule Endoscopy (CPT® 91113) is indicated in the following clinical scenarios:
  - As a primary procedure in individuals with major risk for standard optical colonoscopy or moderate sedation as indicated from an evaluation by a board-certified or board-eligible gastroenterologist, a surgeon trained in endoscopy, or a physician with equivalent endoscopic training AND one of the following:
    - Fecal occult blood test positive OR
    - Multitarget Stool DNA (sDNA) Test positive OR
    - Other evidence of lower GI bleeding in hemodynamically stable individuals
  - As a secondary procedure:
    - For the detection or surveillance of colon polyp(s) if the diagnostic optical colonoscopy was incomplete OR
    - When an incomplete diagnostic optical colonoscopy was performed for either:
      - Multitarget Stool DNA (sDNA) Test Positive OR
      - Other evidence of lower GI bleeding in hemodynamically stable individuals

- Colorectal Cancer Screening
  - Colon Capsule Endoscopy is considered investigational/experimental for Colorectal Cancer Screening and as such is not approvable for this indication.
**Esophageal Capsule Endoscopy (CAPEND-8)**

- Esophageal Capsule Endoscopy (CPT® 91111) is indicated in the following clinical scenario:
  - When endoscopic procedures may be inappropriate or contraindicated, such as:
    - Individuals with non-reversible coagulopathy OR
    - Recent MI OR
    - Evaluation of esophageal varices in cirrhotic individuals who are unable to tolerate or undergo EGD

**Wireless Motility Capsule Endoscopy (CAPEND-9)**

- Wireless motility capsule (CPT® 91112) (also known as SmartPill Gastrointestinal Monitoring System™) is indicated for suspected GI motility disorders after structural issues are ruled out by imaging or traditional endoscopy:
  - Evaluation and/or treatment of individuals with suspected gastroparesis in the absence of obstruction
  - Evaluation of colonic transit in individuals with chronic idiopathic constipation lasting over 6 months
  - Evaluation of small bowel motility
- Motility capsule endoscopy is NOT indicated for individuals with any of the following:
  - History of gastric bezoar
  - Swallowing disorders
  - Dysphagia
  - Suspected strictures or fistulae in the gastrointestinal tract
  - Physiologic gastrointestinal obstruction
  - Recent (within the last 3 months) gastrointestinal surgery
  - Crohn’s disease
  - Diverticulitis
  - Implanted electromechanical medical devices (i.e. pacemaker, infusion pump)

**Background and Supporting Information**

- SmartPill Gastrointestinal Monitoring System™
  - SmartPill™ motility testing features a swallowed sensor-based capsule. SmartPill™ measures pressure, pH, transit time and temperature as it passes through the entire gastrointestinal tract. SmartPill™ assesses gastric emptying time, colonic transit time, whole gut transit time, as well as pressure patterns from the antrum and duodenum.
  - SmartPill™ is FDA-authorized for use in evaluation of gastroparesis and chronic constipation.

**References**

1. Wang A, Banerjee S, Barth BA, et al. Wireless capsule endoscopy. *Gastrointest Endosc.* 2013;78(6):805-815. doi:10.1016/j.gie.2013.06.026
2. Shergill AK, Lightdale JR, Bruining DH, et al. The role of endoscopy in inflammatory bowel disease. Gastrointest Endosc. 2015;81(5). doi:10.1016/j.gie.2014.10.030

3. Katsinelos P, Fasoulas K, Beltis A, et al. Diagnostic yield and clinical impact of wireless capsule endoscopy in patients with chronic abdominal pain with or without diarrhea: A Greek multicenter study. European Journal of Internal Medicine. 2011;22(5). doi:10.1016/j.ejim.2011.08.012

4. Enns RA, Hookey L, Armstrong D, et al. Clinical Practice Guidelines for the Use of Video Capsule Endoscopy. Gastroenterology. 2017;152(3):497-514. doi:10.1053/j.gastro.2016.12.032

5. Lidums I, Cummins AG, Teo E. The role of capsule endoscopy in suspected celiac disease patients with positive celiac serology. Digestive Diseases and Sciences. 2010;56(2):499-505. doi:10.1007/s10620-010-1290-6

6. Rondonotti E, Spada C, Cave D, et al. Video capsule enteroscopy in the diagnosis of celiac disease: a multicenter study. Am J Gastro. 2007;102(8):1624-1631. doi:10.1111/j.1572-0241.2007.01238.x

7. Noujaim MG, Green J, Min M, et al. Carcinoids and capsules: a case series highlighting the utility of capsule endoscopy in patients with small bowel carcinoids. Gastroenterol Res. 2017;10(6):347-351. doi:10.14740/gr937w

8. Hakim FA, Alexander JA, Huprich JE, Grover M, Enders FT. CT-Enterography may identify small bowel tumors not detected by capsule endoscopy: eight years experience at mayo clinic rochester. Digestive Diseases and Sciences. 2011;56(10):2914-2919. doi:10.1007/s10620-011-1773-0

9. Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastro. 2015;110(2):223-262. doi:10.1038/ajg.2014.435.

10. Durno C, Boland CR, Cohen S, et al. Recommendations on surveillance and management of Biallelic Mismatch Repair Deficiency (BMMRD) Syndrome: A consensus statement by the US Multi-Society Task Force on colorectal cancer. Gastroenterology. 2017;152(6):1605-1614. doi:10.1053/j.gastro.2017.02.011.

11. Yadav A, Heigh RI, Hara AK, et al. Performance of the patency capsule compared with nonenteroclysis radiologic examinations in patients with known or suspected intestinal strictures. Gastrointest Endosc. 2011;74:834-839. doi:10.1016/j.gie.2011.05.038.

12. Bond A, Collins P. PTH-010 outcomes after use of patency capsules after video capsule endoscopy. Gut. 2016;65:A222. doi:10.1136/gutjnl-2016-312388.415.

13. Sawada T, Nakamura M, Watanabe O, et al. Clinical factors related to false-positive rates of patency capsule examination. Therap Adv Gastroenterol. 2017;10(8):589-598. doi:10.1177/1756283X17722744.

14. Nemeth A, Kopylov U, Koulouzidis A, et al. Use of patency capsule in patients with established Crohn’s disease. Endoscopy. 2016;48:373-379. doi:10.1055/s-0034-1393560.

15. Rex DK, Boland CR, Dominitz JA, et al. Colorectal cancer screening: Recommendations for physicians and patients from the U.S. Multi-Society Task Force on colorectal cancer. Am J Gastro. July 2017;112(7):1016-1030. doi:10.1038/ajg.2017.174.

16. Han YM, Im JP. Colon capsule endoscopy: where are we and where are we going. Clin Endosc. 2016;49(5):449-453. doi:10.5946/ce.2016.095.

17. Rex DK, Adler SN, Aisenberg J, et al. Accuracy of capsule colonoscopy in detecting colorectal polyps in a screening population. Gastroenterology. 2015;148(5):945-957. doi:10.1053/j.gastro.2015.01.025.

18. Sacher-Huvelin S, Rsson E, Gaudric M, et al. Colon capsule endoscopy vs. colonoscopy in patients at average or increased risk of colorectal cancer. Aliment Pharmacol Ther. 2010;32(9):1145-53. doi:10.1111/j.1365-2036.2010.04458.x.

19. Pasha SF. Applications of colon capsule endoscopy. Curr Gastroenterol Rep. 2018;20(5):22. doi:10.1007/s11894-018-0628-7.

20. Morgan DR, Malik PR, Romeo DP, Rex DK. Initial US evaluation of second generation capsule colonoscopy for detecting polyps. BMJ Open Gastroenterol. 2016;3(1):e000089. doi:10.1136/bmjgast-2016-000089.

21. Spada C, Pasha SF, Gross SA, et al. Accuracy of first and second generation colon capsules in endoscopic detection of colorectal polyps: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14(11):1533-1543. doi:10.1016/j.cgh.2016.04.038.

22. Spada C, Hassan C, Barbaro B et al. Colon capsule versus CT colonography in patients with incomplete colonoscopy: A prospective, comparative trial. Gut. 2015;64(2):272-281.

23. Novitas Solutions, Inc. Future Local Coverage Determination (LCD): Colon Capsule Endoscopy (CCE) (L38807). https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?Lcid=38807&ver=7&bc=CAAAAAAAAE

24. Davidson KW, Barry MJ, Mangione CM, et al. Screening for colorectal cancer. US Preventative Services Task Force recommendation statement. JAMA. 2021;325(19):1965-1977. doi:10.1001/jama.2021.6238.

25. Yang J, Gurudu SR, Koptiuch C, et al. American Society for Gastrointestinal Endoscopy Guideline on the role of endoscopy in familial adenomatous polyposis syndromes. Gastrointest Endosc. 2020;91(5):963-982. doi:10.1016/j.gie.2020.01.028.

26. Camilleri M, Thorne NK, Ringel Y, et al. Wireless pH-motility capsule for colonic transit: Prospective comparison with radiopaque markers in chronic constipation. Neurogastroenterol Motil. 2010;22(8):874-882.
27. Rauch S, Krueger K, Turan A, You J, Roewer N, Sessler DI. Use of wireless motility capsule to determine gastric emptying and small intestinal transit times in critically ill trauma patients. *Journal of Critical Care*. 2012;27(5):534.e7-534.e12.
28. Saad RJ, Hasler WL. A technical review and clinical assessment of the wireless motility capsule. *Gastroenterology and Hepatology*. 2011;7(12):795-804.
29. Tran K, Brun R, Kuo B. Evaluation of regional and whole gut motility using the wireless motility capsule: Relevance in clinical practice. *Therapeutic Advances in Gastroenterology*. 2012;5(4):249-260.
30. Sangnes DA, Safteland E, Bekkelund M, et al. Wireless motility capsule compared with scintigraphy in the assessment of diabetic gastroparesis. *Neurogastroenterol Motil*. 2020;32(4):e13771. doi:10.1111/nmo.13771.
31. Keller J, Bassotti G, Clarke J, et. al. Advances in the diagnosis and classification of gastric and intestinal motility disorders. *Nat Rev Gastroenterol Hepatol*. 2018;15(5):291-308. doi:10.1038/nrgastro.2018.7.
32. Camilleri M, Kuo B, Nguyen L, et al. ACG clinical guidelines: Gastroparesis. *Am J Gastroenterol*. 2022;117(8):1197-1220. doi:10.14309/ajg.0000000000001874.
33. Boland CR, Idos GE, Drno C, et. al. Diagnosis and management of cancer risk in the gastrointestinal hamartomatous polyposis syndromes: recommendations form the US Multi-Society Task Force on colorectal cancer. *Am J Gastroenterol*. 2022;117:846-864.
34. Gupta S, Weiss JM, Axell L, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2023 – May 30, 2023. Genetic/Familial High-Risk Assessment: Colorectal, available at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Genetic/Familial High-Risk Assessment: Colorectal – May 30, 2023. ©2023 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines™, go online to NCCN.org.
35. Pennazio M, Spada C, Eliakim R, et. al. Small bowel capsule endoscopy and device-assisted enteroscopy for diagnosis and treatment of small bowel disorders: European Society of Gastrointestinal Endoscopy (ESGE) clinical guidelines. *Endoscopy*. 2015;47:352-376. doi:10.1055/s-0034-1391855.
36. Rondonotti E, Spada C, Cave D, et. al. Video capsule endoscopy in the diagnosis of celiac disease- a multicenter study. *Am J Gastro*. 2007;102(8):1624-1631. doi:10.1111/j.1572-0241.2007.01238.x.
37. Enns R, Hookey L, Armstrong D, et. al. Clinical practice guidelines for the use of video capsule endoscopy. *Gastroenterology*. 2017;152:497-514. doi:10.1053/j.gastro.2016.12.032.
38. Rokkas T, Niv Y. The role of video capsule endoscopy in the diagnosis of celiac disease: a meta-analysis. *Eur J Gastroenterol Hepatol*. 2012;24(3):303-308. doi:10.1097/MEG.0b013e32834fa914.
39. Ciaccio E, Lewis SK, Bhagat G, Green PH. Coeliac disease and the videocapsule: what have we learned till now. *Ann Transl Med*. 2017;5(9):197. doi:10.21037/atm.2017.05.06.
40. Chang MS, Rubin M, Lewis SK, Green PH. Diagnosing celiac disease by video capsule endoscopy when esophagogastroduodenoscopy (EGD) and biopsy is unable to provide a diagnosis: a case series. *BMC Gastroenterol*. 2012;12:90. doi:10.1186/1471-230X-12-90..
41. Lujan-Sanchis M, Perez-Cuadrado-Robles E, Garcia-Lledo J, et. al. Role of capsule endoscopy in suspected celiac disease: a European multi-centre study. *World J Gastro*. 2017;23(4):703-711. doi:10.3748/wjg.v23.i4.703.
42. Lewis SK, Semrad CE. Capsule Endoscopy and enteroscopy in celiac disease. *Gastroenterol Clin North Am*. 2019;48(1):73-84. doi:10.1016/j.gtc.2018.09.005.
43. Akpunonu B, Hummell J, Akpunonu JD, D SU. Capsule endoscopy in gastrointestinal disease: evaluation, diagnosis, and treatment. *Cleveland Clinic J of Medicine*. 2022;89(4):200-211. doi:10.3949/ccjm.89a.20061.
44. Ferretti F, Branchi F, Orlando S, et. al. Effectiveness of capsule endoscopy and double-balloon enteroscopy in suspected complicated celiac disease. *Clin Gastro and Hepatol*. 2022;20(4):941-949. doi:10.1016/j.cgh.2020.11.010.
45. Rubo-Tapia A, Hill ID, Semrad C, et. al. ACG guidelines update: diagnosis and management of celiac disease. *Am J Gastro*. 2023;118(1):59-76. doi:10.14309/ajg.00000000000002075.
46. Raiteri A, Granito A, Gianperoli A, Catenaro T, Negri G, Tovoli F. Current guidelines for the management of celiac disease: a systematic review and comparative analysis. *World J Gastroenterol*. 2022;28(1):154-175. doi:10.3748/wjg.v28.i1.154.